Institutional researchers requiring detailed technical documentation, bulk ordering logistics, or batch verification records can communicate directly with technical support specialists via our Contact Us page
Common: nausea (especially during dose increasesusually mild and transient), constipation or diarrhea, occasional vomiting, fatigue in first weeks, decreased appetite (the desired effect, but worth noting)
Can I use the same needle size for SubQ and IM GHK-Cu injections
The SURPASS-CVOT trial (estimated completion 2024) is evaluating long-term cardiovascular and other safety outcomes, including pancreatitis, in patients taking tirzepatide for up to 5 years
Post-procedure, you may experience mild redness, swelling, and pinpoint bleeding due to the micro-injuries created by the needles
Semaglutide may go bad if its not properly stored